Prelude Capital Management’s Praxis Precision Medicines PRAX Stock Holding History

Prelude Capital Management’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,064	Closed	-$2.92M	–	1464
2026 Q1	$2.92M	Sell	9,064 -6,974	-43%	-$2.16M	0.22%	110
2025 Q4	$4.73M	Sell	16,038 -12,064	-43%	-$2.25M	0.35%	49
2025 Q3	$1.49M	Buy	28,102 +8,202	+41%	+$398K	0.12%	225
2025 Q2	$837K	Buy	+19,900	New	+$758K	0.08%	301
2023 Q1	–	Sell	-740	Closed	-$26.4K	–	1405
2022 Q4	$26.4K	Buy	+740	New	+$23.1K	﹤0.01%	1166

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Prelude Capital Management's PRAX Position: Q2 2026 in Review

Prelude Capital Management sold out of Praxis Precision Medicines (PRAX) in Q2 2026, closing a stake of 9,064 shares — an estimated $2.92M sold.

Prelude Capital Management first reported a position in PRAX in Q4 2022 and held it in 5 quarters. The position peaked at $4.73M in Q4 2025. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Prelude Capital Management reported no remaining Praxis Precision Medicines position as of Q2 2026 after selling out during the quarter.
Prelude Capital Management sold 9,064 Praxis Precision Medicines shares in Q2 2026, an estimated $2.92M.
Prelude Capital Management first reported a position in Praxis Precision Medicines in Q4 2022 and held it in 5 quarters.
Prelude Capital Management's Praxis Precision Medicines position peaked at $4.73M in Q4 2025.
309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.